NN1177 TFA
Based on 1 Customer Validation
NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
For research use only. We do not sell to patients.
- Purity: 99.22%
- Formula: C206H323N51O66.xC2HF3O2
- Molecular Weight:4570.07 (free base)
-
Storage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CYP3A4 |
NN1177 (0.75-4 nmol/kg, s.c., once daily, 8 weeks) TFA reduces liver fat and inflammatory and fibrosis relevant biomarkers in C57Bl/6 mice fed a fructose and high fat rich diet (NASH model)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 4570.07 (free base)
-
Formula C206H323N51O66.xC2HF3O2
-
Color White to off-white
-
Synonyms
NNC9204-1177 TFA
-
Sequence
His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-{Lys(gGlu-gGlu-Ser-Glu-Ser-gGlu-gGlu-C18 diacid)}-Thr-NH2
-
Sequence Shortening
H-{Aib}-QGTFTSDLSKYLESKRAREFVQWLL-{Lys(γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid)}-T-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H2O : 100 mg/mL (Need ultrasonic)
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17(3):e0264974. [Content Brief]
[2]. Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850. [Content Brief]
[3]. Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz